• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

17
12
12
10
8

COUNTRY

5
4
4
1
1

PRICE

9
32
50
78

PUBLISHED

0
4
8
78

PRODUCT TYPE

75
1
1
1

Generics

(78 Products)

The global generics market is fast growing, driven by demand for cost-effective medicines and new availability of high value products. By now there are 17 generic companies with revenues in excess of US$1 billion, while there were only 12 in 2008/09.

The reports, books, and subscriptions listed under Research and Markets’ Generics category cover every aspect of this industry, such as market trends, forecasts, drivers and restraints, etc. They will allow you to identify business opportunities and assess the strategies of the major players. You can also investigate the latest international and national patent opportunities across a vast number of INNs (international non-proprietary names), taking into account key concerns such as expiry dates, national regulations, etc.

Key players featured in our publications includes Teva Pharmaceutical, Mylan, Sandoz, Watson Pharmaceuticals, Greenstone, Par Pharma, Hospira, Apotex, Mallinckrodt, Dr. Reddy's, and more. Show Less
Read more

India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics - Product Thumbnail Image

India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics

Domestic sales improved in 2014, recovering from the slump in the 2013 caused by the market’s reaction to the new drug pricing policy. In 2015, growth is expected to continue to be healthy, as the...

February 2015
FROM
Sri Lanka Pharma Market Outlook 2015: More beyond Importers & Distributors Sri Lanka Pharma Market Outlook 2015: More beyond Importers & Distributors - Product Thumbnail Image

Sri Lanka Pharma Market Outlook 2015: More beyond Importers & Distributors

With the recent development, Sri Lanka’s aim of developing a pharma industry should be to penetrate the global market since the internal market is not sufficient for any big firm to operate at optimum...

January 2015
FROM
Generic Drug Opportunity Assessment - Ambrisanten (Letairis) Generic Drug Opportunity Assessment - Ambrisanten (Letairis) - Product Thumbnail Image

Generic Drug Opportunity Assessment - Ambrisanten (Letairis)

The branded drug Ambrisentan (brand name Letairis) represents an attractive opportunity for generic drug companies that utilize the provisions under Section 505(j)(2)(A)(vii)(IV) as part of their ANDA-filing...

January 2014
FROM
Generic Drug Opportunity Assessment - Apixaban (Eliquis) Generic Drug Opportunity Assessment - Apixaban (Eliquis) - Product Thumbnail Image

Generic Drug Opportunity Assessment - Apixaban (Eliquis)

The branded drug Eliquis (apixaban) represents an attractive opportunity for generic drug companies that utilize the provisions under Section 505(j)(2)(A)(vii)(IV) as part of their ANDA-filing strategy...

January 2014
FROM
Generic Drug Opportunity Assessment - Asenapine (Saphris) Generic Drug Opportunity Assessment - Asenapine (Saphris) - Product Thumbnail Image

Generic Drug Opportunity Assessment - Asenapine (Saphris)

The branded drug Asenapine (Saphris) represents an attractive opportunity for generic drug companies that utilize the provisions under Section 505(j)(2)(A)(vii)(IV) as part of their ANDA-filing strategy...

January 2014
FROM
Generic Drug Opportunity Assessment - Avanafil (Stendra) Generic Drug Opportunity Assessment - Avanafil (Stendra) - Product Thumbnail Image

Generic Drug Opportunity Assessment - Avanafil (Stendra)

Stendra is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED) Stendra received FDA NDA approval in April 2012 In June 2013, the drug, which will be marketed...

January 2014
FROM
Generic Drug Opportunity Assessment - Boceprevir (Victrelis) Generic Drug Opportunity Assessment - Boceprevir (Victrelis) - Product Thumbnail Image

Generic Drug Opportunity Assessment - Boceprevir (Victrelis)

Boceprevir is a direct acting antiviral drug against the hepatitis C (HCV) virus It is an inhibitor (protease inhibitor) of the HCV non-structural protein 3 (NS3) serine protease Protease inhibitors...

January 2014
FROM
Generic Drug Opportunity Assessment - Dabigatran (Pradaxa) Generic Drug Opportunity Assessment - Dabigatran (Pradaxa) - Product Thumbnail Image

Generic Drug Opportunity Assessment - Dabigatran (Pradaxa)

Pradaxa (dabigatran etexilate) is a novel reversible oral direct thrombin inhibitor that blocks the activity of thrombin, the central enzyme in clot formation It is approved for the primary prevention...

January 2014
FROM
Generic Drug Opportunity Assessment - Dronedarone (Multaq) Generic Drug Opportunity Assessment - Dronedarone (Multaq) - Product Thumbnail Image

Generic Drug Opportunity Assessment - Dronedarone (Multaq)

This branded drug represents an attractive opportunity for generic drug companies that utilize the provisions under Section 505(j)(2)(A)(vii)(IV) as part of their ANDA-filing strategy The Brand Multaq...

January 2014
FROM
Generic Drug Opportunity Assessment - Eltrombopag (Promacta) Generic Drug Opportunity Assessment - Eltrombopag (Promacta) - Product Thumbnail Image

Generic Drug Opportunity Assessment - Eltrombopag (Promacta)

This branded that represents an attractive opportunity for generic drug companies that utilize the provisions under Section 505(j)(2)(A)(vii)(IV) as part of their ANDA-filing strategy The Brand Promacta...

January 2014
FROM
Generic Drug Opportunity Assessment - Etravirine (Intelence) Generic Drug Opportunity Assessment - Etravirine (Intelence) - Product Thumbnail Image

Generic Drug Opportunity Assessment - Etravirine (Intelence)

This branded drug represents an attractive opportunity for generic drug companies The Brand Intelence (etravirine) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency...

January 2014
FROM
Generic Drug Opportunity Assessment - Fesoterodine (Toviaz) Generic Drug Opportunity Assessment - Fesoterodine (Toviaz) - Product Thumbnail Image

Generic Drug Opportunity Assessment - Fesoterodine (Toviaz)

This branded drug represents an attractive opportunity for generic drug companies Fesoterodine is an anticholinergic and competitive muscarinic receptor antagonist After oral administration, fesoterodine...

January 2014
FROM
Generic Drug Opportunity Assessment - Fingolimod (Gilenya) Generic Drug Opportunity Assessment - Fingolimod (Gilenya) - Product Thumbnail Image

Generic Drug Opportunity Assessment - Fingolimod (Gilenya)

This branded drug represents an attractive opportunity for generic drug companies that utilize the provisions under Section 505(j)(2)(A)(vii)(IV) as part of their ANDA-filing strategy The Brand Gilenya...

January 2014
FROM
Generic Drug Opportunity Assessment - Granisetron Sancuso Generic Drug Opportunity Assessment - Granisetron Sancuso - Product Thumbnail Image

Generic Drug Opportunity Assessment - Granisetron Sancuso

This branded drug represents an attractive opportunity for generic drug companies that utilize the provisions under Section 505(j)(2)(A)(vii)(IV) as part of their ANDA-filing strategy The Brand Sancuso...

January 2014
FROM

World Generic Markets Issue

Whilst India's listing in the US Trade Representative's Special report has remained unchanged in 2015, it ironically reveals that US views on the country's intellectual property rights are changing....

May 2015

World Generic Market Report 2015 - Volume III: Global Collaboration Opportunities

Focussing on generic pharmaceuticals, this report looks at companies making up the small and medium business (SMB) spectrum of the industry. Companies covered include generic and biosimilar producers,...

May 2015
Pralatrexate- Comprehensive patent search Pralatrexate- Comprehensive patent search - Product Thumbnail Image

Pralatrexate- Comprehensive patent search

Eliminate unnecessary risk with the industry benchmark in comprehensive patent information. Pipeline Developer is a regularly updated, professional patent search performed by our expert team, which...

May 2015

Mauritius Pharmaceuticals Report

The Mauritius Pharmaceuticals Report features forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics...

April 2015
Analysis of Tyco International Analysis of Tyco International - Product Thumbnail Image

Analysis of Tyco International

Tyco International is active is several industries. It can be broadly described as a supplier of fire and security systems and other related products. North America is the biggest market for Tyco International....

February 2015
FROM
Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry - 2014 Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry - 2014 - Product Thumbnail Image

Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry - 2014

A generic drug is a copy that is the same as a brand-name drug in dosage, safety, strength, how it is taken, quality, performance and intended use. Generic drugs are less expensive because generic...

September 2014
FROM
Loading Indicator

Our Clients

Pfizer, Inc. Sanofi S.A. Abbott Laboratories Ltd. Novartis AG Mallinckrodt Pharmaceuticals Plc. Teva Pharmaceutical Industries Ltd.